Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ATORVASTATIN Cause Malignant neoplasm progression? 85 Reports in FDA Database

Lower Your Cholesterol — The Natural Way

The Oxidized Cholesterol Strategy: a science-backed plan for heart health.

See the Strategy

According to the FDA Adverse Event Reporting System (FAERS), 85 reports of Malignant neoplasm progression have been filed in association with ATORVASTATIN (Atorvastatin calcium). This represents 0.1% of all adverse event reports for ATORVASTATIN.

85
Reports of Malignant neoplasm progression with ATORVASTATIN
0.1%
of all ATORVASTATIN reports
12
Deaths
25
Hospitalizations

How Dangerous Is Malignant neoplasm progression From ATORVASTATIN?

Of the 85 reports, 12 (14.1%) resulted in death, 25 (29.4%) required hospitalization, and 5 (5.9%) were considered life-threatening.

Is Malignant neoplasm progression Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ATORVASTATIN. However, 85 reports have been filed with the FAERS database.

What Other Side Effects Does ATORVASTATIN Cause?

Type 2 diabetes mellitus (7,556) Myalgia (7,155) Drug hypersensitivity (3,929) Drug ineffective (3,865) Fatigue (3,439) Arthralgia (3,338) Rhabdomyolysis (3,286) Dyspnoea (3,137) Nausea (2,888) Asthenia (2,791)

What Other Drugs Cause Malignant neoplasm progression?

PEMBROLIZUMAB (10,111) NIVOLUMAB (9,363) ENZALUTAMIDE (4,696) CARBOPLATIN (4,177) EVEROLIMUS (3,789) PACLITAXEL (3,484) LETROZOLE (3,445) IPILIMUMAB (3,296) FULVESTRANT (3,221) LENVATINIB (2,929)

Which ATORVASTATIN Alternatives Have Lower Malignant neoplasm progression Risk?

ATORVASTATIN vs ATORVASTATIN\EZETIMIBE ATORVASTATIN vs ATOSIBAN ATORVASTATIN vs ATOVAQUONE ATORVASTATIN vs ATOVAQUONE\PROGUANIL ATORVASTATIN vs ATRACURIUM

Related Pages

ATORVASTATIN Full Profile All Malignant neoplasm progression Reports All Drugs Causing Malignant neoplasm progression ATORVASTATIN Demographics